ASRS 2016

    In this interview from ASRS 2016, Dr. Rahul N.  Khurana  discusses results from the phase 4 NEWTON trial,  which switched patients with central retinal vein occlusionsCRVO)  and recurrent  macular edema  from  fixed interval bevacizumab or ranibizumab injections to treat-and-extend aflibercept. After intervention, 19/20 patients were able to increase their treatment interval by an average of 26 days, corresponding to approximately 4 fewer injections a year.  Dr.  Khurana states that aflibercept may be a more durable anti-VEGFagent for eyes with CRVO or those  requiring  chronic therapy.